Previous 10 | Next 10 |
Genmab is a well-managed and vast European biopharma R&D giant. Its partnered products and self-owned pipelines are vast. This is a stock to accumulate at dips. For further details see: Genmab: An European R&D Behemoth With Long-Term Potential
Halvorsen's 13F portfolio value increased from $23.14B to $27.68B. The number of positions increased 71 to 86. Viking Global increased Microsoft, Mecadolibre, and CME Group while reducing Amazon.com and dropping Uber Technologies & JD.com. The top three positions are Microsoft...
Genmab ([[GMAB]] -2.1%) after news that it's discontinuing its Phase 2 study of enapotamab vedotin and dropping development as the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept.“We are committed to developing i...
ImmunoPrecise (IPATF) has entered into a research agreement with Genmab (GMAB), wherein IPA will generate bispecific antibody combinations using Genmab's proprietary DuoBody platform and IPA's proprietary antibodies in the field of infectious disease.As a part of the partnership, Ge...
BioMarin is a leader in rare disease therapy discovery with multiple competitive advantages including scale, expertise, patents and relationships. Two major catalysts for 2021 provide investors with favorable risk/reward skew afforded by a low share price that should not be ignored. ...
BMEZ is a fund that is focused on the healthcare space, more specifically, a focus on the health sciences industry. They overlay this healthcare strategy with an option writing strategy to potentially enhance income. The fund has done exceptionally well since its launch right befo...
The following slide deck was published by Genmab A/S in conjunction with their 2020 Q3 earnings call. For further details see: Genmab A/S 2020 Q3 - Results - Earnings Call Presentation
Genmab A/S (GMAB) announces the initiation of a 480-subject Phase 3 clinical trial comparing bispecific antibody (simultaneously binds to CD3 and CD20) epcoritamab to chemo in patients with diffuse large B-cell lymphoma ((DLBCL)). The primary endpoint is overall survival.The company is co-dev...
Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q3 2020 Earnings Call Nov 4, 2020 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q3 2020 Earnings Call Transcript
Genmab A/S (GMAB) Q3 2020 Earnings Conference Call November 4, 2020 12:00 ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Judith Klimovsky - Chief Development Officer Anthony Mancini - Chief Operating Officer Conferenc...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 01:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...